Member Info for EmeraldCarrots

AKT3 in blood when you have prostate cancer?

====================

In prostate cancer, the AKT signaling pathway—specifically isoforms AKT1, AKT2, and AKT3—undergoes distinct changes in expression and activation, particularly as the cancer progresses, becomes resistant to treatment, or metastasizes. While these changes are most heavily studied within the tumor tissue itself, they reflect in systemic markers and in the behavior of circulating tumor cells.

================================

"and in the behavior of circulating tumor cells".

Cells that the Parsortix machine can catch for study.

Astra RNS 1st May >>>>>>>

https://www.lse.co.uk/rns/AZN/fda-odac-recommends-truqap-in-prostate-cancer-a0vpgaettfsc8cv.html

This is probably why the sp is up. They could use parsortix to find the best candidates for the Astrazeneca cancer drug truqap !!!!!!!!!!

AKT3 in blood when you have prostate cancer?

====================

In prostate cancer, the AKT signaling pathway—specifically isoforms AKT1, AKT2, and AKT3—undergoes distinct changes in expression and activation, particularly as the cancer progresses, becomes resistant to treatment, or metastasizes. While these changes are most heavily studied within the tumor tissue itself, they reflect in systemic markers and in the behavior of circulating tumor cells.

================================

"and in the behavior of circulating tumor cells".

Cells that the Parsortix machine can catch for study.

Truqap (capivasertib) is a targeted therapy that works by inhibiting AKT proteins (AKT1, AKT2, and AKT3), which are enzymes that help cancer cells grow and survive. It specifically targets HR+/HER2– metastatic breast cancer with specific genetic alterations (PIK3CA, AKT1, or PTEN) by blocking these signals to slow tumor progression.

===================================

Cellbxhealth's parsortix (catches CTC's) can help measure HER2 in CTC's as we know................. People that have cancer have circulating tumor cells (CTC's) is their blood. Also Cellbxhealths parsortix can double the chance of finding cancer biomarkers that can guide what treatment is best.

All IMHO.

Iran people firing the missiles and guns and the Iran people negotiating a deal. This is rather worrying! If the people negotiating do a deal will they stop firing??????????????

Noramps.

"No the gain is from a telegram pump stating it is a cure for the new virus"

==========================

That is absurd. They don't make cures for anything. Your first post is not going to impress anyone. I have followed this share for years and IMHO there is a solid reason for the gain today. There are numerous possibilities of good news . Deal with Astrazeneca, Roche, Myriad Genetics, Immatics, Grail, etc.. etc... the list goes on and on. They just need one good break and .............. whoosh!!!!!!!!!!!!!!!!!

All IMHO..

Just not sure what!

Astra RNS 1st May >>>>>>>

https://www.lse.co.uk/rns/AZN/fda-odac-recommends-truqap-in-prostate-cancer-a0vpgaettfsc8cv.html

========================

Truqap drug in trials?

AI Overview

Yes, the ANGLE plc Parsortix® PC1 system is being used to support AstraZeneca’s Truqap (capivasertib) drug development, particularly through the development of specialized assays (laboratory tests) for patient monitoring in clinical trials.Here is how the technology relates to Truqap and AstraZeneca's cancer programs:Assay Development for AstraZeneca: ANGLE completed the development of two specialized assays for AstraZeneca—a prostate cancer Androgen Receptor (AR) assay and a multi-cancer DNA Damage Response (DDR) assay.DDR/PARP Inhibitor Monitoring: The DDR assay is designed to measure treatment responses, particularly for drugs in combination with other cancer therapies. This is relevant to Truqap, as it is an AKT inhibitor often tested in combination with other agents to maximize DNA damage and kill cancer cells, as noted in studies of resistant cancers.Liquid Biopsy Capability: The Parsortix system allows for a "liquid biopsy" (a simple blood draw) to analyze circulating tumor cells (CTCs) without needing invasive tissue biopsies, which can be used to monitor patient responses over time during trials.Prostate Cancer Studies: The developed assays are approved for internal use by AstraZeneca, allowing them to be applied in future large-scale clinical trials, specifically for prostate cancer or other cancer indications where DDR is involved.While Truqap has already been approved for certain breast cancer populations based on the CAPItello-291 trial, these assays could help in monitoring trials for other indications, including prostate cancer.FDA approves capivasertib with fulvestrant for breast cancer16 Nov 2023 — On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestran...U.S. Food and Drug Administration (.gov)Assays complete for AstraZeneca; utility of HER2 demoed24 Mar 2025 — ANGLE has successfully completed three assay development projects as part of its Pharma Services business with existing large phar...Trinity Delta'Marked’ for Stardom?: Truqap | PharmExec16 Aug 2024 — Amid the setback, Susan Galbraith, AstraZeneca's executive vice president of oncology R&D, reaffirmed the company's commitment to ...Pharmaceutical ExecutiveShow allThis is for informational purposes only. For medical advice or a diagnosis, consult a professional. AI responses may include mistakes. Learn more

Truqap drug in trials?

AI Overview

Yes, the ANGLE plc Parsortix® PC1 system is being used to support AstraZeneca’s Truqap (capivasertib) drug development, particularly through the development of specialized assays (laboratory tests) for patient monitoring in clinical trials.Here is how the technology relates to Truqap and AstraZeneca's cancer programs:Assay Development for AstraZeneca: ANGLE completed the development of two specialized assays for AstraZeneca—a prostate cancer Androgen Receptor (AR) assay and a multi-cancer DNA Damage Response (DDR) assay.DDR/PARP Inhibitor Monitoring: The DDR assay is designed to measure treatment responses, particularly for drugs in combination with other cancer therapies. This is relevant to Truqap, as it is an AKT inhibitor often tested in combination with other agents to maximize DNA damage and kill cancer cells, as noted in studies of resistant cancers.Liquid Biopsy Capability: The Parsortix system allows for a "liquid biopsy" (a simple blood draw) to analyze circulating tumor cells (CTCs) without needing invasive tissue biopsies, which can be used to monitor patient responses over time during trials.Prostate Cancer Studies: The developed assays are approved for internal use by AstraZeneca, allowing them to be applied in future large-scale clinical trials, specifically for prostate cancer or other cancer indications where DDR is involved.While Truqap has already been approved for certain breast cancer populations based on the CAPItello-291 trial, these assays could help in monitoring trials for other indications, including prostate cancer.FDA approves capivasertib with fulvestrant for breast cancer16 Nov 2023 — On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestran...U.S. Food and Drug Administration (.gov)Assays complete for AstraZeneca; utility of HER2 demoed24 Mar 2025 — ANGLE has successfully completed three assay development projects as part of its Pharma Services business with existing large phar...Trinity Delta'Marked’ for Stardom?: Truqap | PharmExec16 Aug 2024 — Amid the setback, Susan Galbraith, AstraZeneca's executive vice president of oncology R&D, reaffirmed the company's commitment to ...Pharmaceutical ExecutiveShow allThis is for informational purposes only. For medical advice or a diagnosis, consult a professional. AI responses may include mistakes. Learn more

???????

A deal with the NHS is certainly possible IMHO. They did talk last September. I believe they wanted the NHS to add "dual analysis" to an existing trial. The trial was analysisng lung cancer patients blood to find biomarkers to help guide the best treatment. Of course we know "dual analysis" would enhance tha existing CtDna analysis.................. Hmmmmmmmm

All IMHO.

??????????

Presumably there is news somewhere driving this. Immatics cancer drug trial updaye??? Myriad genetics deal?? Grail been on touch??? NHS deal on "dual analysis"?

............... Confidence from somewhere!

............... Considence from somewhere!

Plus same machine (unique to the USA market) will be put forward for FDA approval later in the year. The other machine, the CYP2C19 should be put forward for FDA approval NEXT MONTH. And people wonder why the sp is up!

.

.

Now up 10.53%

Something brewing.

Mraveragetrader

"He's definitely all in on GDR, hopefully this is going to climb back up to double digits!"

=====================

If I were him I would want a half day meeting to look back at what had been done so far and also see what the future sales plan is. GDR's track record is poor, considering what they have. We should have a load of EU Countries evaluating the Genedrive® MT-RNR1 NOW.

All IMHO.